Daratumumab and brentuximab vedotin combination therapy in T-cell acute lymphoblastic leukemia refractory to conventional chemotherapy and allogeneic stem cell transplant

• Kebede H. Begna,
• Nadine H. Abdallah,
• Michelle Janania-Martinez,
• Abhishek A. Mangaonkar,
• Aruna Rangan,
• Jennifer L. Herrick,
• Naseema Gangat

Affiliations

Kebede H. Begna

Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester

Nadine H. Abdallah

Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester

Michelle Janania-Martinez

Division of Hematology/Oncology, Sanford Cancer Center, Sioux Falls, SD USA

Abhishek A. Mangaonkar

Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester

Aruna Rangan

Department of Laboratory medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester

Jennifer L. Herrick

Department of Laboratory medicine and Pathology, Division of Hematopathology, Mayo Clinic, Rochester

Naseema Gangat

Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester